Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

Date publication

novembre 2011

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AME Shanti

Tous les auteurs :
Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Ame S, Tertian G, Slama B, Fenaux P, Dreyfus F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21803419

Résumé

We evaluated the prognostic value of serum ferritin (SF) level at diagnosis in 318 newly diagnosed IPSS low and int 1 (lower) risk MDS patients included in the French MDS registry, who did not require RBC transfusions and had baseline SF level determination. Increased baseline SF level (>300 ng/ml) was correlated with male gender, more pronounced anaemia, and diagnosis of RARS but had no negative impact on progression to AML or survival.

Référence

Leuk Res. 2011 Nov;35(11):1530-3